MedTrace Logo

COGNIShunt® System for Alzheimer's Disease

NCT00056628 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 250

Last updated 2006-09-12

No results posted yet for this study

Summary

This is a study of the effect on the progression of Alzheimer's Disease of a surgically implanted shunt (tube) to increase the flow of cerebrospinal fluid and improve the clearance of potential neurotoxins from the fluid bathing the brain.

Conditions

  • Alzheimer Disease

Interventions

DEVICE

The COGNIShunt® System

Sponsors & Collaborators

  • Eunoe

    lead INDUSTRY

Principal Investigators

  • Dawn McGuire, MD, Chief Scientific Officer · Eunoe, Inc. 643 Bair Island Road, Redwood City, CA 94063

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
SINGLE_GROUP

Eligibility

Min Age
62 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2001-01-31
Completion
2004-10-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00056628 on ClinicalTrials.gov